Skip to main content
NIHPA Author Manuscripts logoLink to NIHPA Author Manuscripts
. Author manuscript; available in PMC: 2015 Sep 10.
Published in final edited form as: Tetrahedron Lett. 2014 Sep 10;55(37):5191–5194. doi: 10.1016/j.tetlet.2014.07.077

An Enantioselective Synthesis of a MEM-Protected Aetheramide A Derivative

Arun K Ghosh 1,*, Kalapala Venkateswara Rao 1, Siddhartha Akasapu 1
PMCID: PMC4153992  NIHMSID: NIHMS620775  PMID: 25197148

Abstract

Aetheramides A and B are very potent anti-HIV agents. An enantioselective synthesis of a MEM-protected aetheramide A derivative is described. The synthesis was accomplished in a convergent and stereoselective manner. The key reactions involved asymmetric dihydroxylation, asymmetric allylation, asymmetric syn-aldol reactions and asymmetric hydrogenation.

Keywords: Anti-HIV, Anticancer, Natural product, Asymmetric synthesis, Aetheramides


Natural products are traditionally an excellent source of bioactive compounds including a variety of anti-HIV agents.1,2 While anti-HIV drugs developed through drug-design have greatly improved mortality and morbidity of HIV/AIDS patients, there has been a great deal of interest in natural product derived lead structures.3,4 Aetheramides A and B (1 and 2, Figure 1) are unsaturated cyclic depsipeptides isolated from a novel myxobacterial genus Aetherobacter in 2012 by Müller and co-workers.5,6 Both aetheramides A and B contain a unique polyketide segment and a depsipeptide unit. Both these natural products exhibited potent anti-HIV activity with antiviral IC50 values around 15 nM, however, the mechanism of action has not yet been reported.6 Aetheramides also displayed cytostatic activity against human colon carcinoma cell lines with IC50 values of 110 nM. Furthermore, they have shown moderate antifungal activity against Candida albicans at loads of 20 μg/disk. Initial structures of aetheramides were elucidated by extensive NMR and mass spectral analysis, as well as chemical derivatizations and quantum mechanical calculations. The assignment of absolute stereochemistry of four of the six asymmetric centers has been reported. However, the stereochemistry of the C17 and C26 asymmetric centers has not yet been assigned. The potent anti-HIV activity of aetheramides and their unique structural features attracted our interest in their synthesis for structure-activity studies, investigation of mode of action, and design of novel structural variants. Herein, we report our preliminary synthetic efforts leading to an enantioselective synthesis of a protected aetheramide A derivative.

Figure 1.

Figure 1

Structures of aetheramides A and B.

As depicted in Figure 2, aetheramide A features a number of sensitive functionalities that are prone to elimination or epimerization. Particularly, the allylic ether at C26 and the methyl group at C17, both with unknown stereochemistry. As shown, our initial synthetic plan relied upon a cycloamidation reaction to construct the 22-membered macrocycle. Disconnection of the amino acid unit leads to polyketide unit 3, valine, and tyrosine derivative 4. The polyketide segment 3 can be assembled from α,β-unsaturated aldehyde 5 by an Evans aldol reaction. The C26-methyl ether stereochemistry is unassigned, however, we planned to synthesize the 26-(S)-isomer as a starting point using an asymmetric allylation reaction of the corresponding 6-derived aldehyde. This unsaturated ester can be constructed from optically active diol 7 which would be obtained by Sharpless asymmetric dihydroxylation of trans-ethyl cinnamate 8.

Figure 2.

Figure 2

Retrosynthesis of aetheramide A.

The synthesis of homoallylic alcohol 11 is shown in Scheme 1. Optically active syn-diol 7 was prepared in multigram quantities by asymmetric dihydroxylation of ethyl cinnamate using a known procedure.7 Treatment of diol 7 with TBSCl in the presence of pyridine resulted in selective protection of the benzylic alcohol in 50% yield.8 Reaction of the resulting alcohol with MEMCl in the presence of diisopropylethylamine (DIPEA) afforded MEM derivative 9 in 85% yield. Reduction of ester 9 with DIBAL-H provided the corresponding alcohol which was subjected to Swern oxidation to give an aldehyde. Wittig reaction of the aldehyde provided Weinreb amide 10 in 76% yield over 3 steps.9 Reaction of Weinreb amide 10 with DIBAL-H followed by Wittig reaction of the resulting aldehyde afforded unsaturated ester 6 in 83% yield over two steps. Reaction of compound 6 with DIBAL-H followed by Swern oxidation of the resulting alcohol provided the corresponding aldehyde in 88% yield over two steps. Asymmetric allylation of the resulting aldehyde with allyltributylstannane in the presence of a catalytic amount of (S)-BINAP (30 mol%) and AgOTf (30 mol%) afforded (S)-homoallylic alcohol 11 as the only diastereomer in 63% yield (87% BRSM).10

Scheme 1.

Scheme 1

Synthesis of homoallylic alcohol 11.

Synthesis of polyketide segment 3 is outlined in Scheme 2. Reaction of compound 11 with NaH and MeI followed by hydroboration-oxidation provided alcohol 12 in 71% yield over two steps. Alcohol 12 was treated with methanesulfonyl chloride in the presence of Et3N to provide the corresponding mesylate. Reaction of the resulting mesylate with NaCN furnished nitrile 13 in 69% yield over two steps. Nitrile 13 was subjected to DIBAL-H reduction to provide the corresponding aldehyde. Wittig reaction of the resulting aldehyde afforded unsaturated aldehyde 5 in 65% yield over two steps. Aldol reaction of aldehyde 5 and chiral oxazolidinone 14 using Evans protocol afforded syn-aldol product 15 as a single isomer in 82% yield. The alcohol was protected as its TBS ether with TBSOTf in the presence of 2,6-lutidine. Hydrolysis of the oxazolidinone using LiOH-H2O2 provided acid 3 in 70% yield over two steps.

Scheme 2.

Scheme 2

Synthesis of polyketide segment 3.

Synthesis of tyrosine derivative 4 is shown in Scheme 3. Acylamido cinnamate ester 16 was prepared as described in the literature.11 Asymmetric hydrogenation of 16 was carried out with chiral rhodium catalyst using conditions developed by Boaz et al to afford an optically active amino acid derivative.12 Removal of the benzyl protecting group by catalytic hydrogenation furnished amino acid 18 in 75% yield (over two steps) with 98% ee. Deprotection of N-acetyl group of 18 by exposure to methanesulfonic acid followed by reaction of the resulting amine with benzylchloroformate resulted in Cbz-protection of amine as well as formation of O-carbobenzyloxy derivative. Selective hydrolysis of O-carbobenzyloxy group was achieved with K2CO3 in methanol to furnish Cbz-derivative 19 in 48% yield over three steps. Reaction of phenol 19 with MEM-Cl and DIPEA followed by N-methylation13 and subsequent removal of the N-Cbz protecting group afforded amino acid derivative 4 in 51% yield over 3 steps.

Scheme 3.

Scheme 3

Synthesis of optically active amino acid 4.

As shown in Scheme 4, coupling of acid 3 with amine 4 in the presence of BOPCl gave the corresponding amide 20 in 63% yield. The TBS ether of benzyl alcohol was selectively deprotected using TBAF-AcOH (1.6:1). The corresponding alcohol was obtained in 70% yield. Esterification of the resulting alcohol with F-Moc valine using EDC, DIPEA and DMAP afforded compound 21 in 70% (93% BRSM) yield. Hydrolysis of the methyl ester was accomplished using Me3SnOH in refluxing CH2Cl2 to provide the corresponding acid in 82% yield. 14 Fmoc deprotection followed by cycloamidation using BOPCl15 afforded compound 22 in 57% yield over two steps. Treatment of compound 22 with TBAF-AcOH (5:1) followed by oxidation of the resulting alcohol using DMP provided α-keto cycloamide 23 in 53% yield over two steps.16 To complete the synthesis of aetheramide or its stereoisomer, we require to deprotect two MEM-protecting groups. Our subsequent attemps to remove MEM groups from cycloamide 23 under acid-catalyzed conditions however, resulted in elimination of the methyl ether followed by decomposition to a mixture of unidentified products.

Scheme 4.

Scheme 4

Synthesis of cycloamide 23

In conclusion, we have accomplished an enantioselective synthesis of MEM-protected aetheramide A derivative. The synthesis is convergent and features asymmetric dihydroxylation, asymmetric allylation, asymmetric syn-aldol reactions and asymmetric hydrogenation as the key reactions. Our attempted removal of MEM protecting groups resulted in decomposition of the product. Further investigation leading to the total synthesis of aetheramide A structure and structure-activity studies is in progress.

Supplementary Material

01

Acknowledgments

Financial support by the National Institutes of Health (GM53386) is gratefully acknowledged.

Footnotes

Supplementary Data

Supplementary data associated with this article can be found in the online version.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

References and notes

  • 1.Newman DJ, Cragg GM. J Nat Prod. 2012;75:311–335. doi: 10.1021/np200906s. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Singh IP, Bharate SB, Bhutani KK. Curr Sci. 2005;89:269–290. [Google Scholar]
  • 3.De Clercq E. Int J Antimicrob Agents. 2009;33:307–320. doi: 10.1016/j.ijantimicag.2008.10.010. [DOI] [PubMed] [Google Scholar]
  • 4.Zhou X, Liu J, Yang B, Lin X, Yang XW, Liu Y. Curr Med Chem. 2013;20:953–973. [PubMed] [Google Scholar]
  • 5.Garcia R, Gerth K, Stadler M, Dogma IJ, Jr, Müller R. Mol Phylogenet Evol. 2010;57:878–87. doi: 10.1016/j.ympev.2010.08.028. [DOI] [PubMed] [Google Scholar]
  • 6.Plaza A, Garcia R, Bifulco G, Martinez JP, Hüttel S, Sasse F, Meyerhans A, Stadler M, Müller R. Org Lett. 2012;14:2854–2857. doi: 10.1021/ol3011002. [DOI] [PubMed] [Google Scholar]
  • 7.Kim EJ, An KM, Ko SY. Bull Korean Chem Soc. 2006;27:2019–2022. [Google Scholar]
  • 8.Yokomatsu T, Suemune K, Yamagishi T, Shibuya S. Synlett. 1995:847–849. [Google Scholar]
  • 9.Evans DA, Kaldor SW, Jones TK, Clardy J, Stout TJ. J Am Chem Soc. 1990;112:7001–7031. [Google Scholar]
  • 10.Georgy M, Lesot P, Campagne JM. J Org Chem. 2007;72:3543–3549. doi: 10.1021/jo0701942. [DOI] [PubMed] [Google Scholar]
  • 11.Matta MS, Kelley A, Rohde MF. U.S. 1973/3878043 A1 US Patent Application Publication.
  • 12.Boaz NW, Large SE, Ponasik JA, Jr, Moore MK, Barnette T, Nottingham WD. Org Process Res Dev. 2005;9:472–478. [Google Scholar]
  • 13.Kilitoglu B, Arndt DH. Synlett. 2009:720–723. [Google Scholar]
  • 14.Nicolaou KC, Estrada AA, Zak M, Lee SH, Safina BS. Angew Chem Int Ed. 2005;44:1378–1382. doi: 10.1002/anie.200462207. [DOI] [PubMed] [Google Scholar]
  • 15.Liu H, Liu Y, Wang Z, Xing X, Maguire AR, Luesch H, Zhang H, Xu Z, Ye T. Chem Eur J. 2013;19:6774–6784. doi: 10.1002/chem.201203667. [DOI] [PubMed] [Google Scholar]
  • 16.For more details, please see supporting information section.

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

01

RESOURCES